Navigation Links
Taiho Pharmaceutical presenta una solicitud para fabricar y comercializar el nuevo agente antitumoral TAS-102
Date:2/26/2013

TOKIO, 27 de febrero de 2013 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. anunció el 27 de febrero haber presentado una solicitud el día 26 de febrero para la aprobación de la fabricación y marketing del nuevo agente antitumoral nucleósido oral  TAS-102 (combinación de trifluorothymidine (FTD) y tipiracil hydrochloride (TPI)) al Ministerio de Salud , Trabajo y Bienestar de Japón. Taiho Pharmaceutical busca la aprobación de TAS-102 para la indicación de cáncer colorrectal no reseccionable, avanzado y recurrente.  

La solicitud de aprobación se basa en los resultados de un ensayo clínico de fase II (estudio 10040030) realizado en 20 plantas en Japón. Fue un estudio comparativo y de doble ciego de TAS-102 y placebo que reclutó a 172 pacientes con cáncer colorrectal no reseccionable, avanzado y recurrente que fue refractario para la quimioterapia estándar de al menos dos o más regímenes con fluoropyrimidine, irinotecan y oxaliplatin. Los resultados indicaron que el grupo que administró TAS-102 había mejorado las tasas de supervivencia generales (supervivencia general media: 9,0 meses vs. 6,6 meses) y un riesgo significativamente reducido de mortalidad (HR: 0,56, p=0,0011). La reacción secundaria del fármaco más frecuentemente notificada con un grado CTCAE de 3 o más fue neutropenia. La diarrea de grado 3 o superior, la fatiga, náuseas y otras reacciones secundarias no fueron más del 10%. Taiho Pharmaceutical está actualmente procediendo con un ensayo clínico de fase III global de TAS-102 en una población de cáncer colorrectal similar (RECOURSE) con el objetivo final de registro y comercialización global del agente.  

Taiho Pharmaceutical cree que TAS-102 realizará una contribución significativa para los pacientes c
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Taiho Pharmaceutical stellt Zulassungsantrag zur Herstellung und Vermarktung des neuartigen Antitumormittels TAS-102
2. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
3. Taiho Pharmaceutical présente une demande dhomologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
4. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
5. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
6. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
7. Global Pharmaceutical Industry Trends: Procurement Budgets Stay the Same, Marketing Budgets to Experience Slight Decrease
8. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
9. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
10. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
11. UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- The Centers for Medicare & Medicaid ... Network-Quality Improvement Organization (QIN-QIO) contract to a partnership led ... Effective August 1, WVMI will launch Quality Insights Quality ... Pennsylvania , Delaware ... The Network will engage providers and the community in ...
(Date:7/23/2014)... July 23, 2014 Research and ... "Global Electrophysiology Ablation Catheters Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Catheter ablation is ... destroy faulty electrical pathways from sections of the ... as cardiac arrhythmias). Cardiac arrhythmias can be of ...
(Date:7/23/2014)... Creekridge Capital, an independent vendor-focused finance ... so far in 2014 to their portfolio of ... from both the healthcare and technology industries. They ... multi-national companies. Each of these new vendors take ... including: standard leasing products, subscription solutions, a dedicated ...
Breaking Medicine Technology:Announcing a New Regional Approach to Medicare Quality Improvement 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3Creekridge Capital Signs Several New Vendor Partners 2
... WIRE)--May 30, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB: ... a Phase I,trial of INNO-406, an orally ... or,treatment-intolerant chronic myelogenous leukemia, will be,presented at ... Annual,Meeting. The meeting takes place June 1- ...
... from various,clinical studies including a pivotal Phase III trial ... Nexavar (sorafenib) tablets will be presented at the Annual,Meeting ... USA from June 1 - 5, 2007. , On ... be held on June 4, 2007. Starting at around ...
Cached Medicine Technology:Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
(Date:7/23/2014)... voice on the recording was low and calm as the speaker ... with the human immunodeficiency virus (HIV) that causes AIDS: “My heart ... I was on the floor flat on my face boohooing, crying ... recording ended less than 10 minutes later. “Don’t feel like this ... is just God setting you up for something greater,” the anonymous ...
(Date:7/23/2014)... By Kathleen Doheny ... (HealthDay News) -- Weight-loss surgery appears to have an ... symptoms in women, according to a new study. ... a weight-loss surgery program reported having incontinence prior to ... their urinary symptoms either improved or disappeared, said study ...
(Date:7/23/2014)... By Amy Norton ... -- The timing of a girl,s first menstrual period may ... a new study suggests. Researchers have identified over ... of menarche -- a woman,s first menstrual period. The researchers ... a number of diseases ranging from type 2 diabetes to ...
(Date:7/23/2014)... genes have been focused on the regions of the ... the form of amino acids thus proteins. But just ... activator which controls the expression and activity of the ... the role exerted such DNA fragment in tumor development. ... in collaboration with the group of Manel Esteller, ...
(Date:7/23/2014)... likelihood of forming false memories, according to research published ... Association for Psychological Science. , In a study conducted ... of California, Irvine and colleagues, sleep-deprived people who viewed ... false information about the photos were more likely to ... were those who got a full night,s sleep. , ...
Breaking Medicine News(10 mins):Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 2Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 3Health News:Gene Study Gives New Insight Into Puberty in Girls 2Health News:Gene Study Gives New Insight Into Puberty in Girls 3Health News:Sleep deprivation may increase susceptibility to false memories 2
... Hospitals that have better working conditions for nurses are ... to a recent report , led by researchers ... are the number six cause of death in the ... workforce in the nation's hospitals, are in a unique ...
... claimed to have developed super-oxidised water, which speeds up ... is made by passing it through a salt membrane ... fungi. ,The company claims that the solution ... ,We would welcome any safe effective treatment which could ...
... has found how medical science could employ aspirin and ... in certain high-risk individuals. ,The study ... Sanford Markowitz at the Ireland Cancer Center. ... mechanism by which the use of aspirin and nonsteroidal ...
... Army hospital here has conducted an accident victim's multiple organ ... to three individuals. ,The retrievals were conducted ... and the organs were transplanted Thursday on two patients at ... ,Donor Ramesh Chand, 60, whose two sons serve ...
... their birth, healthy babies will look you in the eye. ... 9 months, they will exchange smiles. If they ... to worry. ,There is a growing field ... increasingly looking for early signs in babies of autism, attention ...
... Chinese exporters. After the furore over pet food, it is ... under the scanner. ,The federal government has announced ... Food and Drug Administration decides whether the product contains diethylene ... fluid. ,The imports will be released only if ...
Cached Medicine News:Health News:Better Working Conditions for Nurses Might Decrease Patient Infections 2Health News:Better Working Conditions for Nurses Might Decrease Patient Infections 3Health News:Aspirin may Help to Prevent Colon Cancer in High-risk Individuals 2Health News:Army Hospital Conducts First Multiple Organ Retrieval and Transplantation 2Health News:Watch Out for Signs of Autism in Babies! 2Health News:Watch Out for Signs of Autism in Babies! 3Health News:US Halts Import of Chinese Toothpaste 2
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... SL1 developed by STORZ MEDICAL is the ... in the field of kidney stone lithotripsy ... requirements to be met by orthopaedic apparatus ... been outlined above. The MINILITH SL1 is ...
... transportable, the Dornier Compact Delta lithotripsy system features ... patient. The systems shock source and C-arm are ... avoid the risk of misalignment. The therapy head ... its motorized lateral and horizontal movement and can ...
Used for temporary urine collection. The leg bag is designed for use with the Non-Adhesive Silicone Condom Catheter. Supplied non-sterile. Reusable. Intended for single patient use only....
Medicine Products: